Message Font: Serif | Sans-Serif
 
No. of Recommendations: 6

http://www.bio.org/laws/comments071300.html

There is a nice graph of the database clients at the above address that does not transfer into the text below:

Overview of Incyte and its Business

Incyte is the leading genomic information company in the world. Its business is focused on the discovery and characterization of genes, with an emphasis on those genes that affect response to disease and drugs.

Incyte shares its discoveries on a non-exclusive basis for research purposes with a worldwide network of pharmaceutical, biotechnology and academic collaborators. This nonexclusive business model, based on Incyte's ability to put its discoveries in the hands of as many researchers who can profitably use them, has enabled Incyte to become the leading genomics information company, in terms of numbers of employees, customers, revenues and data collections.

Founded in 1991 with 10 employees, Incyte now employs approximately 1300 employees. Incyte is based in Palo Alto. Approximately 1000 of its employees work in the San Francisco Bay Area; another 200 work in Incyte's St. Louis, Missouri facility, and another 100 are in Cambridge, England.

In the year 2000, Incyte expects to spend approximately $180 million dollars on research and development. Of its approximately 1300 employees, more than 10% hold Ph.D.'s. These statistics demonstrate the capital, both monetary and intellectual, that Incyte is investing in its discovery of genes and the role they play in disease and drug response.

Incyte was the first company to license its information, via database subscriptions, on a nonexclusive basis to pharmaceutical researchers. Incyte pharmaceutical subscribers now number more than 20, and account for approximately 75 percent of worldwide pharmaceutical research and development expenditures, as illustrated by the following slide.

[see the above address]

More recently, Incyte has begun to provide its databases to leading biotechnology and academic researchers. This year, Incyte began to make its information products available on-line, and plans to make all of its information products available through this medium by the end of this year. Incyte also has a vast network of distributors who distribute its products in Europe and Asia. All of these distribution channels are dedicated to the broad dissemination of Incyte's genomic discoveries and their use to alleviate disease.

Based on revenue generation, Incyte has for several years been named as one of the fastest growing companies in Silicon Valley, a region noted for spectacular growth. Based on its 1999 revenues of about $157 million, Incyte had more revenue than any other genomic information company, confirming our position as the number one genomic information company.

Incyte. s nonexclusive business model enables it to derive its revenues by providing useful discoveries to researchers more efficiently than would be possible were they to generate the discoveries themselves. In this way, Incyte has developed a business that leads the world in its sector, while at the same time accelerating the genomics revolution that promises unheard-of benefits for health care.
Print the post  

Announcements

What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.